R & D- medical: biomedical (basic research)

Ended Definitive Contract Awarded Last action

Contract number
HHSN272201300029C
Awardee
Awarding agency
Obligated
$11,016,765

Award facts

Opportunity
Contract value 100% obligated
$11,016,765.47 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition · 18 offers Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Place of performance
West McLean, VA 22102, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Funding Only Action P00016 -$86,820
Funding Only Action P00015 -$9,768
Other Administrative Action P00014 $0
Other Administrative Action P00013 -$88,326
Funding Only Action P00012 -$30,925
Funding Only Action 11 -$590
Funding Only Action 10 -$60,539
Other Administrative Action 9 $0
Other Administrative Action 8 $0
Exercise an Option 7 $763,534
Other Administrative Action 6 $0
Exercise an Option 5 $1,933,277
Other Administrative Action 4 $0
Vendor DUNS or Name Change - Non-Novation 3 $2,823,243
Other Administrative Action 2 $0
Exercise an Option 1 $3,529,059
Original award $2,244,621
Show all 17

About this award

Written by GovTribe AI ·

Leidos, Inc. was awarded an $11.02 million cost-plus-fixed-fee definitive contract by the National Institute of Allergy and Infectious Diseases (NIAID) on September 30, 2013, for biomedical basic research support under the Adjuvant Development Program. The contract, with performance in West McLean, Virginia, and an ultimate completion date of June 30, 2021, involves the development of vaccine adjuvants to enhance immunological responses. The award carries no set-aside designation, reflecting Leidos' status as a large, established contractor. NIAID is a component of the National Institutes of Health responsible for conducting and funding research on infectious diseases and related conditions, making this contract part of the agency's broader portfolio of vaccine development and immunization research initiatives.

The contract engaged a collaborative team of specialized subcontractors to deliver the technical expertise and capabilities required for adjuvant development. Pfenex Inc. provided antigen expertise, consulting services, and recombinant protective antigen (rPA) in both research and good manufacturing practice (GMP) grades. Molecular Diagnostic Services Inc. conducted in vivo assessments, developed immunogenicity assays, and produced documentation for Investigational New Drug submissions, while IIT Research Institute supported preclinical toxicology and safety evaluations. Hawaii Biotech, Inc. contributed vaccine development and antigen platform expertise. This multi-stakeholder approach ensured comprehensive coverage of the research, manufacturing, and regulatory support necessary to advance adjuvant candidates toward clinical development under the broader federal vaccine development infrastructure.

Quick answers

Who was awarded contract HHSN272201300029C?

HHSN272201300029C was awarded to Leidos, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 30, 2013.

How much is contract HHSN272201300029C worth?

The government has obligated $11,016,765 on HHSN272201300029C.

Was contract HHSN272201300029C competed?

The extent of competition for HHSN272201300029C was full and open competition. The government received 18 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login